Chemotherapy in soft tissue sarcoma: The Scandinavian Sarcoma Group experience

Acta Orthopaedica Scandinavica, Supplement

Volumn 70, Issue 285, 1999, Pages 62-68

  Fernberg, Jan Olof ^a   Wiklund, Tom ^b   Monge, Odd ^c   Sundby Hall, Kirsten ^d   Saeter, Gunnar ^d   Alvegård, Thor A ^e   Strander, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALKYLATING AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; PREOPERATIVE TREATMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; ADJUVANT CHEMOTHERAPY; ADULT; DISEASE FREE SURVIVAL; MORTALITY; REGISTER; RISK FACTOR; SARCOMA; SCANDINAVIA; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; HUMANS; IFOSFAMIDE; PROGNOSIS; REGISTRIES; REMISSION INDUCTION; RISK FACTORS; SARCOMA; SCANDINAVIA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 0033141390     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Alvegård T A, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft A M, Blomqvist C, Rydholm A, Stener B, Ranstam J. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989; 7 (10): 1504-13.
2. Antman K H. Chemotherapy of advanced sarcomas of bone and soft tissue. Sem in Oncol 1992; 19 (6) Suppl 12: 13-22.
3. Antman K H, Ryan L, Elias A, Sherman D, Grier H E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma, J Clin Oncol 1989; 7(1): 126-31.
4. Baker L H, Frank J, Fine G, Balcerzak S P, Stephens R L, Stuckey W J, Rivkin S, Saiki J, Ward J H. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 1987; 5 (6): 851-61.
5. Balcerzak S P, Benedetti J, Weiss G R, Natale R B. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 1995; 76 (11): 2248-52.
6. Benjamin R S. Should patients with advanced sarcomas be treated with chemotherapy? Pro. Eur J Cancer 1998; 34 (7): 958-62.
7. Benjamin R S, Wiernik P H, Bachur N R. Adriamycin: a new effective agent in the treatment of disseminated sarcoma. Med Pediatr Oncol 1975; 1 (1): 63-76.
8. Blum R: An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemother Rep Part 3 1975; 6 (2): 247-51.
9. Blum R H, Edmonson J, Ryan L, Pelletier L. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Study Group. Cancer Chemother Pharmacol 1993; 31 (suppl 2): 238-40.
10. Blum R H, Carter S K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80 (2): 249-59.
11. Bokemeyer C, Schmoll H J, Arseniev L et al. Dose intensive treatment for advanced soft tissue sarcoma (STS) with multiple cycles of escalated adriamycin (A)/ ifosfamide (I) followed by G-CSF and peripheral blood stem cell (PBPC) support. Ann Oncol 1994; 5 (suppl 8): 175.
12. Borden E C, Amato D A, Rosenbaum C, Enterline H T, Shiraki M J, Creech R H, Lerner H J, Carbone P P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5 (6): 840-50.
13. Bramwell V H C. Chemotherapy for metastatic soft tissue sarcoma - another full circle? Br J Cancer 1991; 64 (1): 7-9.
14. Bramwell V H C, Eisenhauer E A, Blacksten M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 1995; 6 (8): 847-9.
15. Connelly E F, Budd G T. Ifosfamide in the treatment of soft tissue sarcoma. Seminars in oncology 1996; 23 (3) Suppl 6: 16-21.
16. Creagan E T, Hahn R G, Ahmann D L, Bisel H F. A clinical trial of Adriamycin (NSC-123127) in advanced sarcomas. Oncology 1977; 34 (2): 90-1.
17. Dumontet C, Biron P, Bouffet E, Blay J Y, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transpl 1992; 10 (5): 405-8.
18. Edmonson J H, Ryan L M, Blum R H, Brooks J S J, Shiraki M, Frytak S, Parkinson D R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against soft tissue sarcomas. J Clin Oncol 1993; 11 (7): 1269-75.
19. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman K J. Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7 (9): 1208-16.
20. Enzinger F M, Weiss S W. General considerations. In: Soft tissue tumors. (Ed. Enzinger F M and Weiss S W). Mosby. St Louis 1988: 1-18.
21. Gadd M A, Casper E S, Woodruff J M, McCormack P M, Brennan M F. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Annals of Surgery 1993; 218 (6): 705-12.
22. Gottlieb J A, Baker L H, O'Bryan R M, Sinkovics J G, Hoogstraten B, Quangliana J M, Rivkin S E, Bodey G P Sr, Rodrigues V T, Blumenschein G R, Saiki J H, Coltman C Jr, Burgess M A, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon T E. Adriamycin (NSC 123127) used alone or in combination. Cancer Chemother Rep Part 3 1975; 6 (2): 271-82.
23. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Ortop Scand 1994; 65 (suppl 259): 1-31.
24. Jaques D P, Coit D G, Casper E S, Brennan M F. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (4): 392-7.
25. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13 (7): 1600-8.
26. Levine E A, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson I B, Das Gupta T K. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 1997; 15 (10): 3249-57.
27. O'Bryan R M, Baker L H, Gottlieb J B, Rivkin S E, Balcerzak S P, Grumet G N, Salmon S E, Moon T E, Hoogstraten B. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39 (5): 1940-48.
28. O'Bryan R M, Luce J K, Talley, R W, Gottlieb J A, Baker L H, Bonadonna G. Phase II evaluation of Adriamycin in human neoplasia. Cancer 1973; 32 (1): 1-8.
29. Patel S R, Vadhan-Raj S, Papadopolous N, Plager C, Burgess M A, Hays C, Benjamin R S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15 (6): 2378-84.
30. Pinedo H M, Bramwell V H C, Mouridsen M D, Somers R, Vendrik C P J, Santoro A, Buesa J, Wagener T H, van Oosterom A T, van Unnik J A M, Sylvester R, De Pauw M, Thomas D, Bonadonna G. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer, 1984; 53 (9); 1825-32.
31. Putnam J B Jr, Roth J A, Wesley M N, Johnston M R, Rosenberg S A. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984; 87 (2): 260-8.
32. Reichardt, P. Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma? Pro. Eur J Cancer 1997; 33 (9): 1351-4.
33. Rouessé J, Bourgeois H. Should patients with advanced sarcomas be treated with chemotherapy? Contra. Eur J Cancer 1998; 34 (7): 962-4.
34. Saeter G, Alvegård T A, Monge O R, Strander H, Turesson I, Klepp R, Söderberg M, Wist E, Raabe N, Erlanson M, Solheim O P, Hannisdal E. Ifosfamide and continuous infusion Etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33 (10): 1551-8.
35. Saeter G, Talle K, Solheim O P. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continous-infusion etoposide. Cancer Chemotherapy and Pharmacology 1995; 36: 172-5.
36. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M, van Oosterom A. Doxorubicin versus CYVADIC versus Doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13 (7): 1537-45.
37. Schmidt R A, Conrad III E U, Collins C, Rabinovitch P, Finney A. Measurement and prediction of the short-term response of soft tissue sarcoma to Chemotherapy. Cancer 1993; 72 (9): 2593-601.
38. Schoenfeld D A, Rosenbaum C, Horton J, Wolter J M, Falkson G, DeConti R C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50 (12): 2757-62.
39. Singer S, Corson J M, Demetri G D, Healey E A, Marcus K, Eberlein T J. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995; 221 (2): 185-95.
40. Skapek S X, Shaffer L G, Barker J A. Cytogenetics and the biological basis of sarcomas. Current Opinion in Oncol 1998; 10 (4): 318-25.
41. Steward W P, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, Van Oosterom A T, Warwick J, Greifenberg B, Thomas D, van Glabbeke M. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11 (1): 15-21.
42. Stuart-Harris R, Harper P G, Kaye S B, Wiltshaw E. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 1983; 10 (suppl A): 163-4.
43. Sundby Hall K, Van Geel A N, Blum R, Alvegård T. Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. A randomized phase III study. Abstract EMSOS meeting, 1998.
44. Tierney J F, Stewart L A, Parmar, M K B. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.Lancet 1997; 350: 1647-54.
45. van Geel A N, Pastorino U, Jauch K W, Judson I R, van Coevorden F, Buesa J M, Nielsen O S, Boudinet A, Tursz T, Schmitz P I M. Surgical treatment of lung metastases. Cancer 1996; 77 (4): 675-82.
46. Van Glabbeke M, van Oosterom A T, Oosterhuis J W, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors in advanced soft tissue sarcoma (STS): an overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncol 1994; 5 (suppl 8): 171.
47. van-Haelst-Pisani C M, Buckner J C, Reiman H M, Schaid D J, Edmonson J H, Hahn R G. Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy? Cancer 1991; 68 (11): 2354-58.
48. van Hoesel O G C M, Verweij J, Catimel G, Clavel M, Kerbat P, van Oosterom A T, Kerger J, Tursz T, van Glabbeke M, van Pottelsberghe C, le Bail N, Mouridsen H. Phase II study with docetaxel (Taxoter®) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5 (6): 539-42.
49. Wiklund T A, Blomqvist C, Virolainen M, Elomaa I. Ifosfamide, vincristine, doxorubicin and dacarbazine (IVADIC) in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 1992; 30: 100-4.
50. Wiklund T, Saeter G, Strander H, Alvegård T, Blomqvist C. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer 1997; 33 (3): 357-61.